“Having completed dozens of Susvimo surgeries in my patients with wet, or neovascular, age-related macular degeneration, I’ve ...

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.